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RESUMEN 
Se han sintetizado análogos de tioperamida. Los compuestos han sido ensayados in 
vitro para explorar los factores que permitan diseñar compuestos derivados de la tioperamida 
sin grupo tiourea que mejoren la penetración cerebral. Los compuestos más activos como 
H3-antagonistas contienen un átomo de nitrógeno aromático hetorocíclico sobre la cadena 
lateral. Estos compuestos se han empleado como cabeza de serie para obtener potentes 
H3-antagonistas de histarnina con estructura de ariloxietil y ariloxipropilimidazoles. 
Las relaciones estructura actividad de agonistas se han revisado brevemente. Se han 
estudiado un grupo de análogos de (S-[2-imidazol-4-il)etil]isotiourea (imetit) con el 
objeto de explorar la transición entre agonistas y antagonistas. N,N' -dibutil-[S-[3-(imidazol-
4-il)propil]isotiourea es un muy potente antagonistas que tiene Ki=1.5 nM. 
Palabras clave: Histamina. Ariloxialquilimidazoles. H3-agonistas. H3-antagonistas. 
ABSTRACT 
Analogues of thioperamide have been synthesised and tested in vitro on rat cerebral 
cortex to explore structure-activity relationships with the intention of designing compounds 
which do not possess the thiourea group of thioperamide and which may have improved 
brain penetration. Compounds derived from histamine and having an aromatic nitrogen-
containing heterocyc1e on the side-chain amino group have been found to act as H
3
-
antagonists. These have served as leads to provide aryloxyethyl- and aryloxypropylimidazoles 
which are potent H3 antagonists of histamine. 
Structure-activity relationships for agonists are brief1y reviewed. Analogues of the 
very potent and selective agonist, imetit (S-[2-imidazol-4-yl)ethyl]isothiourea) have been 
studied to explore the transition between agonist, partial agonist and antagonist. The 
isosteric isourea is also a potent agonist. N,N' -Dibutyl-[S-[3-(imidazol-4-yl)propyl]isothiourea 
is a very potent antagonist having K¡= 1.5 nM. 
Key words: Histamine. Aryloxyalkyl-imidazoles. H3-agonists. H3-antagonistas. 
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INTRODUCTION 
GANELLIN, C. R., FKYERAT, A., HOSSElNI, S. K., el a/ii 
The actions of histamine have been characterised pharmacologically as 
being mediated by three subtypes of receptor, designated H¡, H2 and HJ (1-3). 
The HJ receptor was frrst characterised pharmacologicaIly in 1983. It has been 
shown to function as a presynaptic auto receptor inhibiting histamine synthesis 
and histamine release frorn histaminergic neurones in the central nervous system 
(3 , 4) where it modulates the release of histamine into the synaptic cleft. Thus 
activation ofthe HJ receptor by histamine leads to a decrease in the concentration 
released of neurotransrnitter histamine. The HJ receptor also appears to function 
as a heteroreceptor on non-histarninergic axon terminals, modulating the release 
of other important neurotransmitters both in the CNS and the periphery, e.g. , 
acetylcholine, noradrenaline, doparnine, 5-hydroxytryptamine and neuropep-
tides (5). 
The frrst substances used to characterise HJ receptors in 1983 were drawn 
from available compounds and in particular it was shown (3) that burimamide 
(the first compound described as a selective H2-receptor antagonist (2)) was 
actually active at 100 fold lower concentrations in antagonising histamine at the 
putative HJ receptor. More potent H2-antagonists were, however, much less 
active. Thus, there was no correlation between the antagonist potencies of these 
compounds for the established H 2 receptor and the putative HJ receptor. 
Confrrmation of the HJ classification carne in 1987 with the discovery of 
two very potent and selective compounds, namely a chiral agonist (R)a.-
methylhistamine, and a competitive antagonist, thioperamide (Fig. 1) (6). (R)a.-
Methylhistarnine was sorne 15 times more potent than histamine as an H) 
r=f'YNH2 




Fig. 1.- The two selective and potent compounds used to characterise Illstamine H) receptors 
(4). (R)a-Methylhistamine (agonist) and thioperamjde (antagonist). 
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agonist and 100 times more potent than its S enantiomer in inhibiting histamine 
release in vitro from rat cerebral cortex slices. These results indicated that a 
stereochemically dependent interaction takes place and hence provided excellent 
evidence for a new (H3) receptor. 
STRUCTURE-ACTIVITY EXPLORATION OF ANTAGONISTS 
Although thioperamide is a very potent antagonist in vitro (K; = 4.3 nM) 
relatively high doses are required in vivo to inhibit histamine release from the 
brain (in the rat). This could be due to the pharmacokinetic properties of 
thioperamide and might also inc1ude poor penetration of the blood-brain-barrier. 
Unfortunately, thioperamide cannot be used for human studies because ofpotential 
toxicity and another H3-antagonist is required to explore potential therapeutic 
applications. 
It appears that the imidazole ring is an essential structural feature of compounds 
acting at H3 receptors, but in order to use synthetically more accessible starting 
materials for a structure-activity exploration we investigated (7) whether we 
could replace the piperidine substructure of thioperamide by an open chain. H3-
Antagonist potency was found to be dependent on the chain length (Fig. 2, n=2-
4), the most potent compound (n=3) which had approximately one third of the 
potency of thioperamide corresponds to the "ring-opened" analogue of thioperamide. 
UCL No n 
Ki±SEM 
s f) (nM) 11 1108 2 200 
(CH2)nNHCNH 
r=<. 1053 3 13 ± 3 
HN~N 1088 4 20±7 
thioperamide 4 
Fig. 2.- H3-Antagonist poteocy depeods 00 the chain leogth o for N-irnidazolylalkyl-N' -cyclohexyl-
thioureas, tested 0 0 rat cerebral cortex (7). 
The higher homologue (n=4), is the cyc10hexyl analogue of burimamide 
(the first described H2-receptor histamine antagonist) and is approximately 5 
times less potent than thioperamide as an H3 antagonist, whereas burimamide is 
about 60 times les s potent than thioperamide. Comparing these structures one 
may infer that the cyc10hexyl group contributes additional affmity at H3 receptors 
through hydrophobic interaction with lipophilic regions of the receptor and that 
the piperidine ring contributes selectivity by reducing the affmity for H2 receptors. 
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HETEROARYLAMINES AND AROMATIC ETHERS AS ANTAGONISTS 
We were interested in replacing the thiourea group of thioperamide since 
sorne thiourea compounds have been associated with toxic side effects. 
The strong similarities in the structures of these H3 antagonists with H2 
antagonists such as burimamide and imidazolylpropylguanidine (Fig. 3) led us 
to explore whether the polar hydrogen-bonding "urea equivalent" groups in the 
structures of H2 antagonists (Fig. 4) could be used to provide H3 antagonists. 
r=< 





K.i = 70 nM 
imidazolylpropylguanidine 
Ki = 88 nM 
Fig. 3.- H2-Receptor antagonists, burimamide and imidazolylpropylguanidine (SK8F 91486) 





Fig. 4.- Generalised structure which encompasses most of the H)-receptor antagonists (12b). 
Groups such as NH-Het (where Het = an arornatic nitro gen heterocycle) are 
rnuch weaker hydrogen-bonding groups than arnides or thioamides (9) and, 
since hydrogen-bond strength appears to reduce brain penetration, these groups 
had been investigated in the design of the brain-penetrating H2 - antagonist, 
zolantidine (in which Het = 2-benzothiazolyl) (Fig. 5). 
As shown in Table 1 the 2-benzothiazolyl derivative of histamine (UeL 
1029) had K; = 330 nM as an H3 antagonist thus indicating that heterocyc1ic 
groups can be used in structures for antagonist activity at H3 as well as H2 
receptors (11). The 2-pyridyl analogue (UCL 1038) was similarly active and 
introducing a nitro substituent rnarkedly increased the potency (UCL 1040 had 
K; = 29 nM). Other aminopyridines substituted by electronegative groups in the 
5-position, namely CF3 (UCL 1235) and C02Me (UCL 1249) were also markedly 
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O~ N ~ I O~NH-Het 
for zolantidine Het = -----{S "0 
N-V 
Fig. 5.- Zo1antidine, a brain-penetrating H2-receptor agonist which was designed tbrough reducing 
H-bonding capability (lO) . 
more potent. On the other hand, a 5-NH2 group (UCL 1334) did not increase 
potency. We also investigated the replacement of NH by S and this structural 
modification led to a further increase in potency, providing UCL 1199 (Table 
2) having K; = 5 nM ie equipotent with thioperamide. 
Since the 2-amino-5-trifluoromethylpyridyl group (UCL 1235) increased 
potency by 10 fold relative to the corresponding cyclohexy1thiourea (UCL 
1108), the same replacement was made in thioperamide to give compound UCL 
1283 (Table 1). In this case however, the compound was not more potent but 
actually sorne 10 fold less potent than thioperamide. This suggests that the 
thioureas and aminoheterocycles do not bind in the sarne manner to the H3 
receptor. 
Since the nitro group makes the pyridine ring much less basic it seerned 
worthwhile to check whether a ring nitrogen atom was needed at all and so the 
corresponding nitroaniline (UCL 1205) was synthesised; this compound (UCL 
1205) was found to have similar potency to that of the nitropyridine analogue 
(UCL 1040) (Table 2). 
To remove the hydrogen-bond donor character of the nitroaniline, the 
corresponding ether (UCL 1291) was made. This, too, was found to be active 
and therefore it was followed up by making a series of phenoxyethylimidazoles. 
At first, it seemed that the presence of a mesomeric electron-withdrawing group 
enhanced potency. However this did not have to be in the para position and 
meta substituted compounds were also found to be active (e.g. , UCL 1340). The 
most potent was UCL 1306, K; = 5 nM which has a p-carbomethoxy substituent. 
Furthermore, the compound UCL 1344 with a non-polar lipophilic electron-
releasing propyl substituent was also active. 
Higher homologues were also investigated and here, sorne compounds were 
more potent than the phenoxyethyl analogues eg for p-N02 and p-CF3 but others 
were not significantly different (Table 3). 
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Table l.- Heteroaryl derivatives of histamÍne as antagonists at H3-receptors (heteroaryl replacing 
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Table 2.- Aryloxethylimidazoles and related compounds as H3-receptor antagonists tested in 
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19 ± 9 h 
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1384 9±3 
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Table 3.- p-Substituted phenoxyethylimidazoles and phenoxypropyl homologues as H
3
-receptor 
antagonists tested in vitro on rat cerebral eortex. 
Ki ± SEM (nM) 
R n = 2 n=3 
pN02 35 ± 6 6±1 
pCN 9 ± 5 12 ± 3 
pCF3 68 ± 18 14 ± 6 
METHYLHIST AMINES AS AGONISTS 
AH the rnonornethyl-substituted histamines have been synthesised and tested 
for agonist activities at all three histarnine receptor subtypes (Table 4). These 
studies have led to sorne very interesting structure-activity relationships and 
exceHent receptor selectivities (see refs. 12-13). 
Table 4.-Agonist aetivities in vitro of methylhistamines at aH three histarnine receptors, H¡, H2 
and H3, deterrnined in vitro (6, 13). Potencies given relative to histarnine = 100. 
4(5) J3 N 
~'t*9N1t 
2 
H¡ H2 H3 
guinea-pig guinea-pig rat 
ileum atrium brain 
Histamine 100 100 100 
N"-Me <0.01 <0.1 <4 
2-Me 17 4.4 <0.1 
N'-Me 0.42 <0.1 <4 
~-Me 0.83 (rae) 0.89 (rae) 280 (rae) 
a-Me 0.36 (rae) 0.74 (rae) 1550 (R) 
13 (S) 
N-Me 72 74 270 
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N-Methy1ation in the imidazole ring effective1y removes agonist activity at 
aH three receptor subtypes, but N-methylation at the side-chain amino group is 
weH tolerated, and this also holds for side-chain N, N-dimethylation. 
C-Methylation in the imidazole ring renders the compounds inactive as H3 
agonists but introduces selectivity towards H¡ or H2 receptors, 4(5)-methylhistamine 
being a high1y se1ective H 2 agonist. 
C-Methylation in the side chain introduces se1ectivity towards H3 receptors. 
Thus a and ~ methylhistamines have 1ess than 1 % of the potency of histamine 
as agonists at H¡ and H2 receptors, but, remarkably, are more potent than 
histamine as H3 agonists. Furthermore, the introduction of C-methyl also indu-
ces chirality in the mo1ecu1e and, although histamine is achiral, it has been 
shown that H 3-agonist activity main1y resides in the R enantiomer, (R)a-
methylhistamine being sorne 15 times more potent than histamine on rat cere-
bral cortex slices. The eudismic ratio is approximately 100. This compound has 
also been into human volunteer studies (16). (R)a-Methylhistamine, when tritiated 
is especially useful as a radioligand (6). 
Dimethylhistamines have also been investigated as agonists. Thus it has 
been shown that for a,~-dimethylhistamine (Tab1e 5), which has two chiral 
centres, the (R, S) isomer is the most potent having 18 times the potency of 
histamine in vitro on rate cerebral cortex slices (14) and, again, the eudismic 
ratio is approxirnately 100. 
Table 5.-Agonist activities of sorne side-chain substituted dirnethylhistamines at histamine H) 
receptors tested in vitro on rat cerebral corte x slices (14, 15). Potencies given relative to 
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Some studies have been made at joining the alkyl groups into an aliphatic 
ring system (17) and recently a homologous piperidine derivative immepip 
(imidazolylmethylpiperidine) (Fig. 6) has been shown to be equiactive with 
(R)a.-methylhistamine (17, 18). 
HN ~N 
~ 
Fig. 6.-Immepip, a potent H3-receptor agonist which incorporates a piperidine ringo 
IMETIT, A VERY POTENT ISOTHIOUREA AGONIST 
Severallaboratories identified imetit (S-[2-(imidazoI-4-yI)ethyI]isothiourea, 
Fig. 7) as a highly potent and selective H3-receptor agonist (19-22) which is 4 
times more potent than (R)a.-methylhistamine and approximately 60 times more 




Fig. 7.-Imetit, a highly potent H3-receptor agonist. EC50 = 1 nM (i .e., 60 times the potency of 
histamine) as an inhibitor of [3H]histamine release from rat cerebral cortex (19). 
It was of interest to liS to explore the structuraI specificity of imetit for 
agonist action at the H3 receptor. It was found (23) that a single methyl group 
(Table 6, UCL 1123, R¡=CH3, R2=R3=H) was tolerated for agonism but the 
compound was less active than imetit although still 4 times more potent than 
histamine . Increasing the size of the substituent to ethyl afforded a partial 
agonist and increasing the size still further to propyl or cyclohexyI gave 
antagonists. 
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Table 6.- Imetit analogues. From agonist, through partial agonist to antagonists at H) receptors. 
Tested in vitro on rat brain cerebral cortex, agonist (or partial agonist) activities are given as 
EC50's, antagonists as K¡ (± SEM) (23). 
NR1 9 
/ (CH2CH2 SC'NR2R3 
HN V N 
UCL N.O Rl R2 R3 Action EC50 or K¡ (nM) 
Imetit H H H agonist 1.0±0.3 
1532 Me H H agonist 15±3 
1538 Et H H partial agonist 160 ± 60 
1538 Pr H H antagonist 22±8 
1209 C6HII H H antagonist 18±8 
1124 Me Me H antagonist 51 ±22 
1428 H Me Me antagonist ca 500 
1140 Me Me Me antagonist > 500 
A second methyI group, on the same or different isothiourea nitrogen atoms 
converted the compound into an antagonist. Higher aIkyI groups (one on each 
of the two isothiourea nitro gen atoms) enhanced the antagonist potency, affmity 
increasing in proportion to the number of methylene groups up to an optimum 
where RJ = R2 = butyl, which had K, = 5.4 nM. The higher homologue of this 
compound is the imidazolylpropyI-N,NJ - dibutylisothiourea (DeL 1524) had a 
K, = 1.5 nM ie three times more potent than thioperamide (Fig. 8). S-
Ki ± SEM 
UCL No n (n M) 
1176 2 5.4 ± 0.9 
1524 3 1.5 ± 0.3 
1649 4 11 ± 3 
Fig. 8.-Irnidazolylalkyl-N,N' -dibutylisothioureas are potent H) antagonists on rat cerebral 
cortex. 
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Imidazolylpropylisothioureas substituted by aralkyl have been shown to be very 
potent antagonists by van der Goot et al. (22) (Table 7). The p-chlorobenzyl 
derivative, clobenpropit is the most potent H3-antagonist published so far (K; 
=0.12 nM) for antagonising H3 receptors on electrically evoked contractions of 
the isolated guinea-pig ileum (22). The p-iodophenylethyl derivative, iodophenpropit 
has been proposed (24) as a useful radioligand when substituted by 1251. 
Table 7.-Potent isothiourea antagonists at H3 receptors tested in vitro against histamine 
inhibition of electrical\y evoked contractions of the guinea-pig ileuro (22). 
n m R KB(nM) 
2 1-4 H 10-25 
3 1-4 H 1.6-5 
3 1 Cl 0.12 Clobenpropit 
3 2 0.50 Iodophenpropit 
H3-RECEPTOR FUNCTIONS AND POTENTIAL DRUG TARGETS 
No H3 antagonist is yet available for investigation ofthe role ofH3 receptors 
in humans to verify the potential therapeutic applications for the H3-receptor 
histamine antagonists. At present one may only extrapolate from animal data 
and speculate (Table 8). For example, an H3 antagonist entering the brain would 
permit an increase in histamine transmission through histaminergic pathways 
Table 8.- H3 Receptors as sites for drug intervention and potential therapies. 
The physiological consequences of H3 receptor stimulation in man are not proven but possible 
effects are : 
In the brain: 
In the lung: 
In the stomach: 
In the gut: 
reduce alertness? 
reduce severity of asthma? 
reduce gastric acid secretion? 
reduce motility? 
Hence, useful drugs would most likely be: 
Brain-penetrating antagonist 
Peripherally-acting or brain-penetrating agonists. 
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and therefore potentiate the role of histamine in controlling the waking state 
(25) and so act as a stimulant. Histamine H3 receptor antagonists could also 
increase locomotor activity (26) and pituitary hormone (27) secretion, act as 
anticonvulsants (28) and antinociceptives (29), and suppress food intake (30). 
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